278 related articles for article (PubMed ID: 33836133)
1. Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.
Corrigan L; Lowery M
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):475-481. PubMed ID: 33836133
[No Abstract] [Full Text] [Related]
2. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
Rizzo A; Ricci AD; Brandi G
Cancer Treat Res Commun; 2021; 27():100356. PubMed ID: 33799004
[TBL] [Abstract][Full Text] [Related]
3. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Abou-Alfa GK; Macarulla T; Javle MM; Kelley RK; Lubner SJ; Adeva J; Cleary JM; Catenacci DV; Borad MJ; Bridgewater J; Harris WP; Murphy AG; Oh DY; Whisenant J; Lowery MA; Goyal L; Shroff RT; El-Khoueiry AB; Fan B; Wu B; Chamberlain CX; Jiang L; Gliser C; Pandya SS; Valle JW; Zhu AX
Lancet Oncol; 2020 Jun; 21(6):796-807. PubMed ID: 32416072
[TBL] [Abstract][Full Text] [Related]
4. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
Lowery MA; Burris HA; Janku F; Shroff RT; Cleary JM; Azad NS; Goyal L; Maher EA; Gore L; Hollebecque A; Beeram M; Trent JC; Jiang L; Fan B; Aguado-Fraile E; Choe S; Wu B; Gliser C; Agresta SV; Pandya SS; Zhu AX; Abou-Alfa GK
Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):711-720. PubMed ID: 31300360
[TBL] [Abstract][Full Text] [Related]
5. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
Zhu AX; Macarulla T; Javle MM; Kelley RK; Lubner SJ; Adeva J; Cleary JM; Catenacci DVT; Borad MJ; Bridgewater JA; Harris WP; Murphy AG; Oh DY; Whisenant JR; Lowery MA; Goyal L; Shroff RT; El-Khoueiry AB; Chamberlain CX; Aguado-Fraile E; Choe S; Wu B; Liu H; Gliser C; Pandya SS; Valle JW; Abou-Alfa GK
JAMA Oncol; 2021 Nov; 7(11):1669-1677. PubMed ID: 34554208
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study.
Fan B; Abou-Alfa GK; Zhu AX; Pandya SS; Jia H; Yin F; Gliser C; Hua Z; Hossain M; Yang H
Cancer Chemother Pharmacol; 2024 May; 93(5):471-479. PubMed ID: 38278871
[TBL] [Abstract][Full Text] [Related]
7. Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.
Lavacchi D; Caliman E; Rossi G; Buttitta E; Botteri C; Fancelli S; Pellegrini E; Roviello G; Pillozzi S; Antonuzzo L
Pharmacol Ther; 2022 Sep; 237():108170. PubMed ID: 35296436
[TBL] [Abstract][Full Text] [Related]
8. Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-
Aguado-Fraile E; Tassinari A; Ishii Y; Sigel C; Lowery MA; Goyal L; Gliser C; Jiang L; Pandya SS; Wu B; Bardeesy N; Choe S; Deshpande V
Future Oncol; 2021 Jun; 17(16):2057-2074. PubMed ID: 33709779
[No Abstract] [Full Text] [Related]
9. Ivosidenib Boosts OS in Cholangiocarcinoma.
Cancer Discov; 2021 Dec; 11(12):2953-2954. PubMed ID: 34635569
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of ivosidenib versus chemotherapy for previously treated IDH1-mutant advanced intrahepatic cholangiocarcinoma in Taiwan.
Chen KA; Huang WM; Chen EY; Ho PK; Chueh CH; Wen YW; Chen MH; Chiang NJ; Tsai YW
BMC Cancer; 2024 May; 24(1):622. PubMed ID: 38778261
[TBL] [Abstract][Full Text] [Related]
11. Ivosidenib: an investigational drug for the treatment of biliary tract cancers.
Angelakas A; Lamarca A; Hubner RA; McNamara MG; Valle JW
Expert Opin Investig Drugs; 2021 Apr; 30(4):301-307. PubMed ID: 33683991
[No Abstract] [Full Text] [Related]
12. FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.
Casak SJ; Pradhan S; Fashoyin-Aje LA; Ren Y; Shen YL; Xu Y; Chow ECY; Xiong Y; Zirklelbach JF; Liu J; Charlab R; Pierce WF; Fesenko N; Beaver JA; Pazdur R; Kluetz PG; Lemery SJ
Clin Cancer Res; 2022 Jul; 28(13):2733-2737. PubMed ID: 35259259
[TBL] [Abstract][Full Text] [Related]
13. Ivosidenib: A Review in Advanced Cholangiocarcinoma.
Frampton JE
Target Oncol; 2023 Nov; 18(6):973-980. PubMed ID: 37855990
[TBL] [Abstract][Full Text] [Related]
14. Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis.
Rimini M; Burgio V; Antonuzzo L; Rimassa L; Oneda E; Lavacchi D; Personeni N; Ratti F; Pedica F; Della Corte A; Persano M; De Cobelli F; Aldrighetti L; Scartozzi M; Cascinu S; Casadei-Gardini A
Target Oncol; 2022 Sep; 17(5):591-596. PubMed ID: 36114954
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of ivosidenib for the treatment of
Tella SH; Mahipal A
Expert Opin Pharmacother; 2022 Dec; 23(17):1879-1885. PubMed ID: 36257911
[TBL] [Abstract][Full Text] [Related]
16. [Ivosidenib in the treatment of patients with cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy].
Rabehi T; Quesada S
Bull Cancer; 2023 Dec; 110(12):1230-1231. PubMed ID: 37704495
[No Abstract] [Full Text] [Related]
17. Clinical development of IDH1 inhibitors for cancer therapy.
Zarei M; Hue JJ; Hajihassani O; Graor HJ; Katayama ES; Loftus AW; Bajor D; Rothermel LD; Vaziri-Gohar A; Winter JM
Cancer Treat Rev; 2022 Feb; 103():102334. PubMed ID: 34974243
[TBL] [Abstract][Full Text] [Related]
18. Evaluating ivosidenib for the treatment of acute myeloid leukemia.
Donker ML; Ossenkoppele GJ
Expert Opin Pharmacother; 2020 Dec; 21(18):2205-2213. PubMed ID: 32808831
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
Fan B; Mellinghoff IK; Wen PY; Lowery MA; Goyal L; Tap WD; Pandya SS; Manyak E; Jiang L; Liu G; Nimkar T; Gliser C; Prahl Judge M; Agresta S; Yang H; Dai D
Invest New Drugs; 2020 Apr; 38(2):433-444. PubMed ID: 31028664
[TBL] [Abstract][Full Text] [Related]
20. Ivosidenib, an IDH1 inhibitor, in a patient with recurrent,
Tejera D; Kushnirsky M; Gultekin SH; Lu M; Steelman L; de la Fuente MI
CNS Oncol; 2020 Sep; 9(3):CNS62. PubMed ID: 32716208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
